Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has a partnership agreement with Merck & Co. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California.

AMEX:ARMP

Armata Pharmaceuticals, Inc.

Last Close

2.21

25/09 13:50

Market Cap

96.89M

Beta: 0.54

Volume Today

450

Avg: 13.05K

PE Ratio

−2.27

PFCF: −2.59